Scientists from Harvard, Oxford and other institutions have developed a blood test to predict risk in patients with Hypertrophic Cardiomyopathy (HCM), the most common inherited heart disease. Measuring NT-proBNP levels helps identify high-risk patients early, enabling timely treatment and potentially preventing serious complications like heart failure or atrial fibrillation.